35,615 Shares in Dynavax Technologies Corporation $DVAX Acquired by AXQ Capital LP

AXQ Capital LP purchased a new position in Dynavax Technologies Corporation (NASDAQ:DVAX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 35,615 shares of the biopharmaceutical company’s stock, valued at approximately $354,000.

Several other large investors also recently bought and sold shares of the company. Marshall Wace LLP lifted its position in shares of Dynavax Technologies by 107.2% during the second quarter. Marshall Wace LLP now owns 1,814,934 shares of the biopharmaceutical company’s stock worth $18,004,000 after purchasing an additional 939,076 shares in the last quarter. Man Group plc increased its stake in Dynavax Technologies by 925.5% during the 2nd quarter. Man Group plc now owns 447,847 shares of the biopharmaceutical company’s stock worth $4,443,000 after buying an additional 404,175 shares during the period. Pacer Advisors Inc. lifted its holdings in Dynavax Technologies by 3,639.9% in the 3rd quarter. Pacer Advisors Inc. now owns 322,119 shares of the biopharmaceutical company’s stock worth $3,199,000 after buying an additional 313,506 shares in the last quarter. Squarepoint Ops LLC boosted its position in Dynavax Technologies by 222.3% in the 2nd quarter. Squarepoint Ops LLC now owns 435,577 shares of the biopharmaceutical company’s stock valued at $4,321,000 after buying an additional 300,421 shares during the last quarter. Finally, Qube Research & Technologies Ltd purchased a new position in Dynavax Technologies in the 2nd quarter valued at about $2,844,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Insider Buying and Selling at Dynavax Technologies

In related news, COO David F. Novack sold 114,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $15.64, for a total value of $1,782,960.00. Following the sale, the chief operating officer owned 63,344 shares of the company’s stock, valued at approximately $990,700.16. This trade represents a 64.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 2.98% of the company’s stock.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX opened at $15.50 on Thursday. The company has a quick ratio of 6.94, a current ratio of 7.62 and a debt-to-equity ratio of 0.41. Dynavax Technologies Corporation has a fifty-two week low of $9.20 and a fifty-two week high of $15.73. The firm has a 50-day simple moving average of $15.14 and a 200 day simple moving average of $12.07. The company has a market cap of $1.82 billion, a PE ratio of -41.89 and a beta of 0.97.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on DVAX shares. Wall Street Zen raised Dynavax Technologies to a “strong-buy” rating in a research report on Saturday, February 14th. William Blair downgraded Dynavax Technologies from an “outperform” rating to a “hold” rating in a report on Wednesday, December 24th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $21.00.

Dynavax Technologies Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.